Uppsala, Sweden, 2018-01-24 08:30 CET (GLOBE NEWSWIRE) --
The board of directors of Oasmia Pharmaceutical AB (publ) ("Oasmia" or the
"Company") has resolved on a directed issue of no more than 34,838,709
warrants. Subsequently, all warrants have been subscribed for, of which
Arwidsro Investment AB has subscribed for 24,193,548 warrants and MGC Capital
Ltd has subscribed for 10,645,161 warrants.
Each warrant entitles to subscribe for one share in the company, at a
subscription price of SEK 3.10, during the period from registration of the
warrants with the Swedish Companies Registration Office until and including 15
August 2019. Upon full exercise of the warrants, the share capital will
increase by SEK 3,483,870.90. The warrants are issued free of charge.
The reason for the issue was set out in a press release on 2 January 2018.
Including, inter alia, that the company in connection with Arwidsro Investment
AB's and MGC Capital Ltd's commitment to make available loans to the company,
has undertaken to issue warrants as resolved today. The company has ensured
that the warrants are issued on market terms by evaluating different funding
options and negotiating the terms of the loans. If all of the warrants were
exercised, the company would receive a capital contribution of approximately
SEK 108 million.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new
generations of drugs in the field of human and veterinary oncology. The
company's product development aims to create and manufacture novel nanoparticle
formulations and drug-delivery systems based on well-established cytostatics
which, in comparison with current alternatives, show improved properties,
reduced side-effects, and expanded applications. The company's product
development is based on its proprietary in-house research and company patents.
Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange
(OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).
For more information, please contact:
Anders Blom, CFO
Tel: +46 (0)18 50 54 40
E-mail: anders.blom@oasmia.com
Attachment:
https://cns.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=660620© 2018 GlobeNewswire
